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Angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers can decrease hemoglobin, causing anemia
and this may be an independent risk factor for chronic kidney
disease progression. We studied the relationship between a
decline in hemoglobin and outcome in 1513 patients with
type 2 diabetes and kidney disease by a post hoc analysis of
the RENAAL Study (Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan) with an average
follow-up of 3.4 years. The relationship between baseline and
year-1 hemoglobin and treatment on end-stage renal disease
(ESRD) and ESRD or death was evaluated using multivariate
Cox models (covariates: baseline hemoglobin, proteinuria,
serum albumin, serum creatinine, and year-1 hemoglobin).
Compared with placebo, losartan treatment was associated
with a significant decrease of hemoglobin, with the largest
between-group difference at 1 year. After adjustment, there
were significant relative risk reductions for losartan
compared with placebo for ESRD and for ESRD or death
regardless of the baseline hemoglobin even in those patients
with a baseline hemoglobin below 120 g l1. Hence, the
renoprotective properties of losartan were maintained
despite a significant lowering of the hemoglobin
concentration.
Kidney International (2008) 73, 630–636; doi:10.1038/sj.ki.5002746;
published online 19 December 2007
KEYWORDS: anemia; angiotensin receptor antagonist; end-stage renal
disease; glomerular filtration rate; hemoglobin; losartan
Angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) are renoprotective in
diabetics with proteinuria and chronic kidney disease (CKD)
and recommended as first-line treatment for patients with
diabetes, hypertension, and microalbuminuria.1 Both drug
classes may reduce hemoglobin concentration in patients
with hypertension or CKD;2–5 reductions 410 g l1 have
been reported in pediatric, renal transplant, and hemodialysis
populations.6–10 The lowering of hemoglobin observed
during treatment with ACEIs and ARBs may occur as early
as 3 weeks after initiation of therapy, with nadir reported at
3 months, and is usually reversible after ACEI or ARB
discontinuation.2–5 The mechanism whereby ACEIs and
ARBs cause anemia is at least in part related to blockade of
erythropoietic effects of angiotensin II on red cell precursors
and improved renal blood flow secondary to renal efferent
vasodilation, which improves oxygenation.3,11–13
Several studies indicate that anemia may be a risk factor
for progression of CKD. We reported that lower baseline
hemoglobin concentration was associated with significant
increase in risk for end-stage renal disease (ESRD) in the
Reduction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan (RENAAL) study.14 In a randomized,
controlled study of early versus late treatment for anemia in
non-diabetic CKD patients, early treatment with erythro-
poietin slowed progression to a composite endpoint of
doubling of serum creatinine, ESRD, or death.15 In contrast,
two recently published randomized, controlled trials in
patients with CKD did not demonstrate beneficial outcomes
of erythropoietin-stimulating agent therapy on ESRD.16,17
Still, because anemia may be a risk factor for progression of
CKD, there is concern that ACEI or ARB treatment may
lower hemoglobin and thereby attenuate the renoprotective
effects of these drugs. Therefore we sought to determine
whether treatment with losartan was associated with
significant and persistent reduction in hemoglobin concen-
tration over time, and whether such reduction attenuates its
renoprotective properties as measured by ESRD, the
composite of ESRD or death, and proteinuria in patients
with type 2 diabetes and nephropathy in the RENAAL study.
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RESULTS
Baseline characteristics
Baseline characteristics were summarized by baseline hemo-
globin category and/or treatment group (Table 1). For
combined treatment groups (data not shown), baseline
hemoglobin o120 g l1 group (mean 108 g l1; n¼ 499,
38.8%) compared with the X120 g l1 group (mean
137 g l1; n¼ 788, 61.2%) included more females, Asians,
blacks, and Hispanics, and fewer whites. Systolic blood
pressure, pulse pressure, serum creatinine (176.8 versus
159.1 mmol l1, Po0.001), proteinuria (geometric mean
urine albumin to creatinine ratio (UACR) 1306.3 versus
1002.4 mg g1, Po0.001), and phosphorus were higher and
diastolic blood pressure, estimated glomerular filtration rate
(eGFR) (35.3 versus 43.0 ml min 1.73 m2, Po0.001), and
serum albumin (37 versus 39 g l1, Po0.001) were lower in
the hemoglobin o120 g l1 group. The losartan (n¼ 648)
and placebo (n¼ 639) groups had similar baseline character-
istics, including hemoglobin and proteinuria (Tables 1 and
2), even when divided into baseline hemoglobin o120
and X120 g l1 categories (Table 1). Triglyceride levels were
higher at baseline in the losartan group with hemoglobin
o120 g l1, and in the placebo group with hemoglobin
X120 g l1.
Changes in laboratory measurements during follow-up
Hemoglobin. Both treatment groups had mean baseline
hemoglobin concentration of 125 g l1, which decreased to
119 g l1 in the losartan group (n¼ 84) and 118 g l1 (n¼ 54)
in the placebo group at year 4 (Table 2). Decline in the
losartan group occurred at year 1 and stabilized afterwards,
whereas the decline in the placebo group was gradual over 4
years. Between-group differences in changes from baseline
were significant at years 1 (4 g l1, Po0.001), 2 (4, Po0.001),
and 3 (3, P¼ 0.014), but not at year 4 (2, P¼ 0.528). A
similar pattern was seen in the hemoglobin X120 g l1
category; however, decreases in hemoglobin in the losartan group
with baseline hemoglobin o120 g l1 category were 3–4 g l1
until year 4 when the decrease was 8 g l1 (n¼ 24 at year 4).
Proteinuria. Proteinuria decreased in both treatment
groups during the 4-year follow-up, but the decrease in the
losartan group was significantly greater at each annual
measurement (all Po0.001) (Table 2).
ESRD and ESRD or death
There were significant risk reductions for losartan versus
placebo treatment for ESRD in baseline hemoglobin
o120 g l1 (relative risk reduction (RRR) 35.8%, 95%
confidence interval (CI) 13.4–52.4, P¼ 0.004) and X120 g l1
(RRR 30.6%, 95% CI 4.3–49.7, P¼ 0.026) categories, while
risk reductions for ESRD or death were significant in the
baseline hemoglobin o120 g l1 category (RRR 28.6%, 95%
CI 9.1–43.9, P¼ 0.006) and non-significant in theX120 g l1
category (RRR 19.1%, 95% CI 2.5–36.1, P¼ 0.079)
(Table 3). Risk reductions were comparable for baseline
hemoglobino120 andX120 g l1 categories, as indicated by
non-significant interaction tests (P¼ 0.637 for ESRD;
P¼ 0.362 for ESRD or death).
Table 1 | Baseline characteristics for patients with hemoglobin measurements up to year 1
Baseline Hb o120 g l1 n=499 Baseline Hb X120 g l1 n=788 Combined n=1287
Characteristic Losartan n=261 Placebo n=238 Losartan n=387 Placebo n=401 Losartan n=648 Placebo n=639
Age, years 59.7 (7.5) 59.3 (7.7) 60.2 (7.1) 61.0 (7.1) 60.0 (7.7) 60.4 (7.4)
Male, n (%) 102 (39.1) 106 (44.5) 297 (76.7) 304 (75.8) 399 (61.6) 410 (64.2)
Female, n (%) 159 (60.9) 132 (55.5) 90 (23.3) 97 (24.2) 249 (38.4) 229 (35.8)
Race or ethnicity, n (%)
Asian 49 (18.8) 48 (20.2) 61 (15.8) 64 (16.0) 110 (17.0) 112 (17.5)
Black 60 (23.0) 48 (20.2) 48 (12.4) 44 (11.0) 108 (16.7) 92 (14.4)
White 91 (34.9) 93 (39.1) 210 (54.3) 219 (54.6) 301 (46.5) 312 (48.8)
Hispanic 57 (21.8) 47 (19.7) 63 (16.3) 70 (17.5) 120 (18.5) 117 (18.3)
Other 4 (1.5) 2 (0.8) 5 (1.3) 4 (1.0) 9 (1.4) 6 (0.9)
Systolic BP, mm Hg 152.3 (19.9) 154.9 (20.8) 151.0 (17.7) 151.2 (19.7) 151.5 (18.6) 152.6 (20.2)
Diastolic BP, mm Hg 79.7 (10.1) 81.1 (10.9) 83.8 (10.0) 82.9 (10.6) 82.2 (10.2) 82.2 (10.7)
UACR, mg g1 (GM) 2100.0 1972.5 1602.6 1519.7 1803.0 1688.3
(1914.6) (1704.1) (1611.9) (1380.2) (1755.8) (1523.5)
(1330.6) (1318.1) (1029.6) (996.9) (1142.7) (1106.2)
Serum creatinine, mmol l1 175.6 (43.5) 175.6 (44.8) 155.4 (37.3) 157.1 (39.5) 163.5 (41.1) 164.0 (42.5)
eGFR, ml min1 1.73 m2 34.9 (11.0) 35.8 (12.2) 43.3 (11.4) 42.8 (12.3) 39.9 (12.0) 40.2 (12.7)
Triglycerides, mmol l1 (GM*) 2.3 (2.0) 2.1 (1.3) 2.5 (2.1) 2.8 (2.8) 2.4 (2.1) 2.6 (2.4)
(1.9) (1.8) (2.1) (2.3) (2.0) (2.1)
Serum albumin, g l1 36 (4) 37 (4) 39 (4) 39 (4) 38 (4) 38 (4)
Hemoglobin, g l1 108 (9) 107 (9) 137 (12) 136 (12) 125 (18) 125 (18)
Calcium, mmol l1 2.31 (0.13) 2.30 (0.13) 2.36 (0.12) 2.37 (0.12) 2.34 (0.13) 2.34 (0.13)
Phosphorus, mmol l1 1.34 (0.21) 1.33 (0.19) 1.20 (0.19) 1.20 (0.19) 1.26 (0.21) 1.25 (0.20)
BP, blood pressure; eGFR, estimated glomerular filtration rate; GM, geometric mean; Hb, hemoglobin; UACR, urinary albumin:creatinine ratio.
*P-values between hemoglobin strata=0.054 (mean) and 0.41 (geometric mean).
Continuous data: mean (standard deviation) unless otherwise noted.
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When change in hemoglobin at year 1 was entered into
the model, there were significant risk reductions for
losartan versus placebo treatment for ESRD in baseline
hemoglobin o120 g l1 (RRR 32.0%, 95% CI 5.4–51.1,
P¼ 0.022) and X120 g l1 (RRR 39.6%, 95% CI 13.8–57.7,
P¼ 0.005) categories, as well as for ESRD or death in
baseline hemoglobin o120 g l1 (RRR 25.5%, 95%
CI 1.3–43.8, P¼ 0.040) and X120 g l1 (RRR 30.4%,
95% CI 7.9–47.3, P¼ 0.011) categories (Table 3). Risk
reductions were similar for baseline hemoglobin o120
and X120 g l1 categories as indicated by non-significant
interaction tests (P¼ 0.890 for ESRD; P¼ 0.874 for ESRD
or death).
ESRD risk in prevalent and new anemia categories
Risk reductions for ESRD in the losartan group compared
with the placebo group favored losartan for all prevalent and
new anemia categories except the improving anemia category
(11 ESRD events among 76 patients), and were significant in
the new anemia (hazard ratio 0.58, 95% CI 0.35–0.94,
P¼ 0.029), persistent anemia (hazard ratio 0.62, 95% CI
0.44–0.88, P¼ 0.008), and missing data (hazard ratio 0.37,
95% CI 0.21–0.67, P¼ 0.001) categories (Table 4).
DISCUSSION
The principal new finding from these analyses from the
RENAAL study is that the renoprotective effect of long-term
administration of losartan to patients with type 2 diabetes
and nephropathy was maintained despite a significant decline
in hemoglobin concentration. Furthermore, benefits on
ESRD, ESRD or death, and proteinuria in the losartan
treatment group were maintained when hemoglobin de-
creased. Patients with lower hemoglobin (persistent anemia
and new anemia) may be at greater risk for ESRD. A
significant benefit of losartan treatment was seen for these
populations. Patients enrolled in the RENAAL trial had
advanced nephropathy as indicated by average baseline serum
creatinine of 168.0 mmol l1 (1.9 mg per 100 ml) and UACR
of 1.9 g g1 18 and were at high risk for progression to ESRD
over the time of the study. Moreover, patients with lower
hemoglobin concentration at baseline had lower glomerular
filtration rate, lower serum albumin level, increased protein-
uria, and were more likely to be female, Asian, Hispanic, or
black. These participants may be at higher risk for
progression of kidney disease and subsequently more likely
to benefit from losartan therapy even in the setting of a lower
or declining hemoglobin concentration.
Table 2 | Baseline and annual hemoglobin and proteinuria by treatment group
Losartan Placebo
n Mean Changea n Mean Changea Differenceb P-valuec
Hemoglobin (g l1) for combined hemoglobin groups
Baseline 751 125 0 762 125 0 — —
Year 1 648 119 6 639 123 2 4 o0.001
Year 2 554 118 8 529 122 4 4 o0.001
Year 3 348 119 10 309 122 7 3 0.014
Year 4 84 119 12 54 118 10 2 0.528
Hemoglobin (g l1) for baseline hemoglobin o120 g l1
Baseline 300 107 0 291 107 0 — —
Year 1 261 105 3 238 108 1 4 0.001
Year 2 214 104 4 186 108 1 5 o0.001
Year 3 113 105 3 84 107 1 2 0.353
Year 4 24 97 8 15 111 5 13 0.013
Hemoglobin (g l1) for baseline hemoglobin X120 g l1
Baseline 451 137 0 471 136 0 — —
Year 1 387 128 9 401 132 4 5 o0.001
Year 2 340 127 11 343 130 7 4 o0.001
Year 3 235 126 13 225 128 9 4 0.003
Year 4 60 127 14 39 121 16 2 0.431
UACR (mg g1) n GM GMR n GM GMR % Reduction P-valuec
Baseline 751 1163.9 1 762 1146.8 1 — —
Year 1 737 785.7 0.7 731 1137.8 1.0 32.6 o0.001
Year 2 639 654.0 0.6 617 966.5 0.9 31.5 o0.001
Year 3 535 496.4 0.5 498 770.4 0.8 34.4 o0.001
Year 4 243 392.9 0.5 205 707.5 0.8 43.2 o0.001
GM, geometric mean; GMR, geometric mean ratio over baseline; UACR, urinary albumin:creatinine ratio.
% Reduction: 100 (1ratio of GMR for losartan versus GMR for placebo).
aMean of change, with change calculated as difference between time indicated and baseline as measured for each participant.
bDifference of changes between treatment groups.
cP-values compare differences from no change.
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Recent data indicate that patients who develop anemia
during treatment with an ACEI are at greater risk for left
ventricular dysfunction than those with prevalent anemia.19
However, our findings indicate that even those with anemia
(hemoglobin concentration o120 g l1) at baseline were
likely to derive renal benefit from treatment with losartan
whether hemoglobin declined, remained stable, or improved
over time (Table 4). Therefore, our findings are applicable to
a growing population of patients with type 2 diabetes in
the United States at risk for onset and progression of
nephropathy.
In our prior analysis of the RENAAL study, we found that
baseline hemoglobin concentration was an independent
predictor of the outcomes of ESRD and ESRD or death.14
Hemoglobin concentration just below normal (o138 versus
4138 g l1) portended increased risk for ESRD, and lower
hemoglobin (o113 versus 4138 g l1) portended increased
risk for ESRD or death.14 The mechanism whereby anemia
increases risk for disease progression in diabetic nephropathy
is unknown. Anemia has been implicated as a trigger of
kidney fibrosis and excessive renal sympathetic activity,
which could contribute to declining kidney function in
diabetics with nephropathy.20,21 Two recent studies reported
renal outcomes of anemia treatment. In the Cardiovascular
Risk Reduction by Early Anemia Treatment with Epoetin
beta (CREATE) study, patients with baseline GFR
15–35 ml min1 1.73 m2 and hemoglobin 110–125 g l1
who were treated with erythropoietin to target hemoglobin
130–150 versus 105–115 g l1 for approximately 3 years had
no significant difference in risk for the primary composite
cardiovascular endpoint, significantly higher risk for time to
ESRD (dialysis, P¼ 0.03), and no significant difference in
slope of eGFR.16 In the Correction of Hemoglobin and
Outcomes in Renal Insufficiency (CHOIR) study, patients
with baseline GFR 15–50 ml min1 1.73 m2 and hemoglobin
o110 g l1 who were treated with erythropoietin to target
hemoglobin of 135 versus 113 g l1 were at significantly
higher risk for the primary composite cardiovascular end-
point (P¼ 0.03) with no significant difference in ESRD.17
The mechanism of ACEI- and ARB-associated anemia is
not completely understood, but appears to be at least in part
due to inhibition of erythropoiesis. Early studies investigated
erythropoietin levels, and more recent studies have investi-
gated the role of insulin-like growth factor-1, insulin-like
growth factor-1-binding proteins, and N-acetyl-seryl-aspar-
tyl-lysyl-proline (AcSDKP), as well as angiotensin II receptors
in bone marrow. ACEIs and ARBs inhibit the growth of
erythroid precursors but lower hemoglobin via distinct
Table 3 | Event rates and risk reductions of treatment for endpoints of ESRD and ESRD or death
Losartan Placebo
Bsl Hb, g l1 N K (rate) n K (rate) RRR (95% CI) P-valuea Interactionb
ESRD
Cox bsl onlyc o120 300 81 (99.2) 291 104 (141.9) 35.8 (13.4–52.4) 0.004 0.637
X120 451 66 (48.5) 471 90 (64.8) 30.6 (4.3–49.7) 0.026
Cox bsl+Yr 1 Hbd o120 261 69 (93.6) 238 81 (125.7) 32.0 (5.4–51.1) 0.022 0.890
X120 387 56 (46.3) 401 76 (62.1) 39.6 (13.8–57.7) 0.005
ESRD or death
Cox bsl onlyc o120 300 126 (154.3) 291 148 (201.9) 28.6 (9.1–43.9) 0.006 0.362
X120 451 129 (94.8) 471 152 (109.4) 19.1 (2.5–36.1) 0.079
Cox bsl+Yr 1 Hbd o120 261 98 (132.9) 238 105 (163.0) 25.5 (1.3–43.8) 0.040 0.874
X120 387 96 (79.4) 401 114 (93.1) 30.4 (7.9–47.3) 0.011
bsl, baseline; CI, confidence interval; ESRD, end-stage renal disease; Hb, hemoglobin; K (rate), # of events per 1000 patient-years of follow-up; RRR, relative risk reduction;
Yr, year.
aTreatment effect of losartan versus placebo.
bInteraction test between treatment group and hemoglobin group (o120 or X120 g l1).
cMultivariate Cox model with baseline log urinary albumin:creatinine ratio, serum albumin, serum creatinine, and hemoglobin as covariates.
dMultivariate Cox model with baseline log urinary albumin:creatinine ratio, serum albumin, serum creatinine, and hemoglobin and change in hemoglobin at year 1 as
covariates.
Table 4 | Hazard ratios for reductions in ESRD by losartan for baseline and year-1 anemia categories
Losartan Placebo
Hemoglobin category n K (rate) n K (rate) HR (95% CI) P-value
No anemia Bsl Hb X120 g l1; Yr 1 X120 g l1 259 23 (27.6) 310 39 (39.9) 0.68 (0.40–1.15) 0.152
Improving anemia Bsl Hb o120 g l1; Yr 1 X120 g l1 26 4 (53.7) 50 7 (48.2) 2.04 (0.44–9.50) 0.366
New anemia Bsl Hb X120 g l1; Yr 1 o120 g l1 121 32 (90.8) 87 37 (159.8) 0.58 (0.35–0.94) 0.029
Persistent anemia Bsl Hb o120 g l1; Yr 1 o120 g l1 232 63 (95.9) 182 71 (147.5) 0.62 (0.44–0.88) 0.008
Missing Hb at Yr 1 98 21 (96.6) 122 37 (147.3) 0.37 (0.21–0.67) 0.001
Bsl, baseline; CI, confidence interval; ESRD, end-stage renal disease; Hb, hemoglobin; HR, hazard ratio; K (rate), # of events per 1000 patient-years of follow-up; Yr, year.
Multivariate Cox model with hemoglobin category and baseline urinary albumin:creatinine ratio, serum albumin, serum creatinine, and hemoglobin as covariates.
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mechanisms. AcSDKP is degraded by angiotensin-converting
enzyme and in the presence of ACEI, but not ARB, treatment.
AcSDKP level may be increased during ACEI treatment,
thereby inhibiting hematopoiesis.22–24 ACEIs also reduce
insulin-like growth factor-1 levels and are unable to enhance
erythropoiesis.25 Insulin-like growth factor-1 levels are high
in patients with erythrocytosis. ACEIs also decrease inter-
leukin-12, another stimulator of erythropoiesis.25 Renal
efferent vasodilation may improve renal blood flow, leading
to improved oxygenation. ARBs interfere with the bone
marrow renin–angiotensin system, which utilizes angiotensin
type 1 and 2 receptors.11 The angiotensin type 1 receptor may
be important in influencing entry of stem cells into the cell
cycle in patients with post-transplant erythrocytosis.26
Furthermore, in vitro studies have demonstrated that
angiotensin infusion can increase erythropoiesis, but still
requires erythropoietin.13
Our study has important implications for treatment of
anemia in patients with CKD due to type 2 diabetic
nephropathy. First, clinicians should be aware that use of
losartan in diabetics with CKD who are not anemic
(hemoglobin 4120 g l1) may become so when therapy is
initiated. Based on the experience with other ARBs, we would
expect that the effects on hemoglobin attributed to losartan
in our study are representative of a class effect and not
limited specifically to losartan; however, we studied losartan
only in this analysis. Second, the magnitude of hemoglobin
decline associated with long-term losartan use in diabetes
with nephropathy is relatively small, on average 6 and 14 g l1
in the losartan group at 1 and 4 years respectively. Third, the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (NKF KDOQITM) clinical practice guide-
lines recommend anemia evaluation at hemoglobin
o120 g l1, and treatment with erythropoiesis-stimulating
agents when hemoglobin is o110 g l1.27 RENAAL was
conducted before the era of widespread erythropoietin use
in pre-dialysis CKD patients; only 18 patients received
erythropoietin at baseline despite the fact that 21.7% of
RENAAL study participants had a baseline hemoglobin
p110 g l1. In current clinical practice, ACEI- or ARB-
induced decreases in hemoglobin might be treated by
appropriate dosing of erythropoiesis-stimulating agents and
iron to maintain hemoglobin 110–120 g l1.
There are some limitations to these analyses. RENAAL was
not designed specifically to study anemia; therefore, specific
history related to anemia (such as hemolysis, menorrhagia, or
gastrointestinal hemorrhage) was not collected, nor were
laboratory data regarding other factors related to anemia
(such as nutritional deficiencies (iron, B12, folate), red blood
cell survival, hemoglobin electrophoresis, expression of
hypoxia-inducible factor, and toxic metabolites of uremia)
obtained. An additional limitation of this analysis is the lack
of information on treatment of low hemoglobin in the
RENAAL trial. Although we did not observe a statistically
significant interaction between categories of baseline hemo-
globin and renal outcomes because the power to detect such
interaction was low, we cannot exclude the possibility that
baseline hemoglobin was a modifier of the effect of losartan
on hemoglobin and outcome. It is important to note that the
magnitude of the mean change in hemoglobin over 1 year
in the present study was 6 g l1 in the losartan group.
A hemoglobin decline o10 g l1 may be important when it
changes categorization (e.g., at 120 g l1) and treatment for
anemia is considered. For example, treatment of anemia as
well as more aggressive management of other comorbidities
could have been undertaken and thereby contributed to the
beneficial effects observed with treatment assignment to
losartan. Because the number of subjects with data at 4 years
of follow-up was small, we are unable to comment on results
of longer-term treatment with losartan on anemia and renal
outcomes in diabetes with nephropathy. It is important to
note that in our study, all participants had CKD attributed to
type 2 diabetes and nephropathy; therefore, this analysis may
not be generalized to non-diabetic CKD populations.
In conclusion, these analyses from the RENAAL study
indicate that losartan-associated decline in hemoglobin
occurred in patients with type 2 diabetes and nephropathy.
While even mild anemia may be a risk factor for progression
of CKD and for poor outcomes, these analyses suggest that
the beneficial effects of treatment with losartan in this patient
population on ESRD, ESRD or death, and proteinuria
persisted in the presence of hemoglobin decrease. Further
prospective studies are warranted to study risk of anemia
associated with ARBs, as well as optimal level of hemoglobin
to minimize renal and cardiovascular complications in the
CKD population.
MATERIALS AND METHODS
RENAAL was a randomized, prospective, double-blind, placebo-
controlled study of effects of treatment with losartan in 1513
patients with type 2 diabetes and nephropathy over 3.4 years
(mean).18 Nephropathy was defined as baseline serum creatinine
4132.6 mmol l1 (1.5 mg per 100 ml) in males, 114.9mmol l1
(1.3 mg per 100 ml) in females or males o60 kg weight) to
265.2 mmol l1 (3.0 mg per 100 ml) and proteinuria (UACR4
300 mg g1 or a 24-h urine protein 4500 mg). Patients were treated
to goal systolic blood pressure o140 mm Hg and diastolic
o90 mm Hg. Patients could receive additional antihypertensive
agents, excluding ACEIs and ARBs, if goal blood pressure was not
achieved. The study protocol was approved by all relevant ethics
committees and all patients provided written informed consent.
Samples for hemoglobin analysis were collected in potassium
EDTA tubes at room temperature and analyzed in regional reference
laboratories by photometric absorbance using Coulter model GEN-S
and STKS (Beckman Coulter Inc., Fullerton, CA, USA). Measure-
ments were cross-validated monthly using normal and abnormal
samples in a central laboratory.16 Proteinuria was measured on spot
urine samples as UACR (mg per g) or 24-h urine collections (mg per
day), and eGFR was calculated by the Modification of Diet in Renal
Disease study equation.28
Primary endpoints for the present analyses were risk reductions
for ESRD and the combined endpoint of ESRD or death. ESRD was
defined as need for chronic dialysis or renal transplantation.18 Death
was defined as death from any cause. All deaths and ESRD events
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were adjudicated by an independent adjudication committee.
Secondary endpoint was change in proteinuria, which was
determined annually. Hemoglobin concentration was measured at
baseline and annually. In order to determine whether losartan
treatment would be associated with significant and persistent
reduction in hemoglobin concentration as compared with placebo
treatment, we evaluated change in hemoglobin concentration from
baseline annually to the end of the study. To study the relationship
between losartan, hemoglobin concentration, and outcomes, the
population was divided into two groups: baseline hemoglobino120
and X120 g l1. The rationale for this categorization was based on
the following: (1) 120 g l1 is the hemoglobin concentration at
which the 2002 NKF KDOQI guidelines recommend evaluation for
anemia in patients with CKD;29 (2) the treatment goal for patients
with CKD and anemia attributed to erythropoietin deficiency is
110–120 g l1,30 and (3) blood hemoglobin concentration 120 g l1
has become synonymous with renal anemia based on these factors.
The wider-range treatment goal of 110–130 g l1 has been advocated
by 2006 NKF KDOQI guidelines to prevent cycling due to narrow
therapeutic target rather than because of new evidence for ceiling
hemoglobin.30
Statistical analysis
All randomized patients were included in this post hoc analysis.
Participants were dichotomized by baseline hemoglobin (o120 or
X120 g l1) and treatment group (losartan or placebo). To
determine change from baseline to year 1, year 1 was defined in
the data analysis plan as the last value after randomization before
ESRD and up to and including day 410 after randomization; similar
methods were used for years 2, 3, and 4 with day ranges as follows:
411–775, 776–1140, and 1141–1505, respectively. Forty-five partici-
pants had missing hemoglobin values at baseline; for these patients
baseline hemoglobin values were imputed according to baseline
characteristics before randomization.
Baseline characteristics were summarized for patients with
hemoglobin measured at year 1 for losartan and placebo groups
within hemoglobin o120 and X120 g l1 groups. For longitudinal
data during the study, mean value and change from baseline for
hemoglobin, stratified by hemoglobin 120 g l1, were provided at
baseline and annually. The change in hemoglobin from baseline was
measured for each participant with measured follow-up hemoglo-
bin, and then averaged. The between-group difference was
compared by Student’s t-test. Differences over time between baseline
hemoglobin o120 and X120 g l1 categories were analyzed by
testing for an interaction between reduction in hemoglobin during
losartan or placebo administration depending on baseline hemo-
globin value. Regarding the interaction model, we included
treatment group (losartan or placebo), baseline hemoglobin
category (o120 or X120 g l1), and their interaction factor
(cross-product terms) in the model as covariates. For proteinuria
(UACR), the corresponding calculation was done on the natural
logarithm scale; geometric mean, geometric mean ratio over
baseline, and reduction were determined.
Number and exposure rate (number of events per 1000 patient-
years of follow-up) of ESRD alone and ESRD or death events were
summarized for treatment groups and baseline hemoglobin
categories. RRR and 95% CI for each group were determined using
a Cox proportional hazards model with the following baseline
covariates in the multivariate analysis: log proteinuria, serum
albumin, serum creatinine, and hemoglobin.14,27 A second Cox
model similar to the first one also adjusted for change in
hemoglobin at year 1 because this is the first available hemoglobin
concentration value that would reflect the expected 3-month nadir
after starting losartan. In addition, we explored treatment effect of
losartan on ESRD by 5 categories: no effect, improving, new,
persistent anemia, and missing hemoglobin at year 1 based on
hemoglobin o120 or X120 g l1 at baseline and year 1. The fifth
group included 226 patients. A two-sided P-value o0.05 defined
statistical significance.
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